Market Overview

3 Biotech IPOs Debuting This Week

Share:

This week, there are twelve companies that are planning to go public. Below are details on three biotech companies set to debut.

Zosano Pharma Corp (NASDAQ: ZSAN) is a biotechnology company that is developing ZP Patch Technology, which is a needle-free delivery system.

The company is offering 4.3 million shares and the underwriters are Ladenburg Thallmann and Roth Capital Partners. Zosano attempted to go public in late July of last year, but the deal was pushed out.

The price range is $10-$12, and the market cap at the middle of the range is $127 million. The IPO prices Monday night and trades Tuesday.

Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here

Presbia PLC (NASDAQ: LENS) is an ophthalmic device company that is developing the Presbia Flexivue Microlens. This microlens is 3 mm in diameter and is implanted in the corneal pocket to help patients focus on near objects.

Related Link: What Investors Are Watching At Zogenix

The company is offering 4.2 million shares and the sole underwriter is Jefferies.

The price range is $11-$13 and the market cap at the middle of the range is $160 million. The IPO prices Tuesday night and trades Wednesday.

Flex Pharma Inc (NASDAQ: FLKS) is a biotechnology company that is developing treatments for nocturnal leg cramps.

Cristoph Westphal is the co-founder and CEO of the company. He also co-founded Sirtris Pharmaceuticals in 2004 and currently serves on the board of directors of Verastem Inc (NASDAQ: VSTM) and OvaScience Inc (NASDAQ: OVAS).

The company is offering 4.6 million shares and the underwriters are Jefferies, Piper Jaffray, JMP Securities, Cantor Fitzgerald and Roth Capital Partners.

The price range is $12-$14, and the market cap at the middle of the range is $221 million. The IPO prices Wednesday night and trades Thursday.

Posted-In: News Previews FDA IPOs Trading Ideas

 

Related Articles (FLKS + LENS)

View Comments and Join the Discussion!

Are Apple Shares Going To Move Higher On Quarterly Earnings? This Analyst Thinks So

AUD/USD Steady